Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals Ownership Summary
Zentalis Pharmaceuticals is owned by 77.26% institutional investors, 13.54% insiders, and 9.20% retail investors. Matrix capital management company, lp is the largest institutional shareholder, holding 19.39% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.
ZNTL Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Zentalis Pharmaceuticals | 77.26% | 13.54% | 9.20% |
Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
Industry | Biotech Stocks | 306.59% | 11.10% | -217.69% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Matrix capital management company, lp | 13.96M | 19.39% | $16.19M |
Blackrock | 4.82M | 6.80% | $19.71M |
Vanguard group | 3.27M | 4.60% | $9.91M |
State street | 3.05M | 4.31% | $12.48M |
Acadian asset management | 2.80M | 3.89% | $3.24M |
Morgan stanley | 1.95M | 2.75% | $7.98M |
Opaleye management | 1.77M | 2.49% | $5.36M |
Blackrock funding, inc. /de | 1.74M | 2.42% | $2.02M |
Almitas capital | 1.60M | 2.22% | $1.86M |
Tang capital management | 1.55M | 2.15% | $1.80M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Mayo clinic | 187.14K | 25.27% | $765.41K |
Matrix capital management company, lp | 13.96M | 7.27% | $16.19M |
Tybourne capital management (hk) | 1.48M | 4.96% | $1.71M |
Opaleye management | 1.77M | 0.94% | $5.36M |
Almitas capital | 1.60M | 0.47% | $1.86M |
Decheng capital | 1.32M | 0.39% | $1.54M |
5am venture management | 490.00K | 0.35% | $1.48M |
Pfizer | 953.83K | 0.19% | $1.11M |
Stonepine capital management | 109.01K | 0.12% | $126.45K |
Boxer capital | 450.00K | 0.10% | $1.84M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Balyasny asset management | 970.86K | 0.00% | 970.86K |
Morgan stanley | 1.95M | 0.00% | 913.31K |
Opaleye management | 1.77M | 0.94% | 800.50K |
Tybourne capital management (hk) | 1.48M | 4.96% | 516.67K |
Jpmorgan chase | 859.71K | 0.00% | 370.51K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Fmr | 182.31K | - | -4.89M |
Eventide asset management | - | - | -4.48M |
Blackrock funding, inc. /de | 1.74M | - | -2.49M |
Vanguard group | 3.27M | 0.00% | -1.34M |
T. rowe price investment management | - | - | -1.33M |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Cubist systematic strategies | 180.22K | 0.00% | 180.22K | $546.08K |
Bnp paribas arbitrage, snc | 176.29K | 0.00% | 176.29K | $534.16K |
Bridgeway capital management | 175.00K | 0.01% | 175.00K | $530.25K |
Ameriprise financial | 146.67K | 0.00% | 146.67K | $444.42K |
Rbf capital | 80.00K | 0.00% | 80.00K | $92.80K |
Sold Out
Holder | Change |
---|---|
Gamma investing | -2.00 |
Farther finance advisors | -10.00 |
Nelson, van denburg & campbell wealth management group | -11.00 |
Ifp advisors | -23.00 |
Riggs asset managment | -23.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Jun 30, 2025 | 115 | -12.21% | 55,620,773 | 31.52% | 77 | 2.22% | 58 | -1.69% | 42 | -14.29% |
Mar 31, 2025 | 134 | -8.22% | 58,450,755 | -9.27% | 81 | 0.99% | 60 | -34.07% | 49 | 63.33% |
Dec 31, 2024 | 139 | 0.72% | 61,824,330 | -12.88% | 86 | 0.87% | 85 | 19.72% | 28 | -26.32% |
Sep 30, 2024 | 137 | -4.86% | 70,963,212 | -7.43% | 99 | 0.85% | 71 | -13.41% | 38 | -5.00% |
Jun 30, 2024 | 144 | 2.13% | 76,655,527 | -9.95% | 108 | 0.75% | 82 | 5.13% | 40 | 11.11% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Eventide Healthcare & Life Sciences I | 2.83M | 3.96% | -2.12M |
Vanguard US Total Market Shares ETF | 1.89M | 2.64% | - |
Eventide Gilead N | 1.64M | 2.30% | -1.94M |
Vanguard Total Stock Mkt Idx Inv | 1.55M | 2.14% | -33.78K |
Fidelity Growth Compy Commingled Pl O | 1.16M | 1.63% | - |
FIAM Small Cap Core CIT Cl B | 886.80K | 1.25% | 11.50K |
Fidelity Growth Compy Commingled Pl S | 881.46K | 1.24% | -280.77K |
FIAM Small Cap Core Composite | 866.20K | 1.22% | 289.81K |
Fidelity Small Cap Growth | 734.93K | 1.03% | - |
PRIMECAP Odyssey Aggressive Growth | 741.40K | 1.03% | -172.00K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Apr 30, 2025 | Myers Scott Dunseth | - | Buy | $29.37K |
Feb 06, 2025 | Bruns Ingmar | Chief Medical Officer | Buy | $45.66K |
Feb 03, 2025 | Vultaggio Vincent | PAO and Interim PFO | Sell | $4.48K |
Feb 03, 2025 | Lackner Mark | Chief Scientific Officer | Sell | $24.59K |
Feb 03, 2025 | Paul Andrea | Chief Legal Officer | Sell | $22.64K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q2 | 1 | - |
2025 Q1 | 4 | 4 |
2024 Q4 | - | 1 |
2024 Q2 | - | 2 |
2024 Q1 | - | 6 |
ZNTL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools